Reasons for exclusion from thrombolytic therapy following acute ischemic stroke

Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors’ center.

[1]  K Yaffe,et al.  Frontotemporal dementia progresses to death faster than Alzheimer disease , 2005, Neurology.

[2]  C. Janson,et al.  Essay: White daisies on my mind (Requiem for an Alzheimer patient) , 2005, Neurology.

[3]  California Acute Stroke Pilot Registry Investigators.  Prioritizing interventions to improve rates of thrombolysis for ischemic stroke , 2005 .

[4]  J. Martí-Fàbregas,et al.  Benefits of a Prehospital Stroke Code System , 2005, Cerebrovascular Diseases.

[5]  Fernando Vinuela,et al.  MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia , 2004, Stroke.

[6]  Alexander Norbash,et al.  Mechanical Thrombolysis in Acute Ischemic Stroke With Endovascular Photoacoustic Recanalization , 2004, Stroke.

[7]  M. Hammer,et al.  Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. , 2004, Archives of neurology.

[8]  Joseph P Broderick,et al.  Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.

[9]  G. Wikholm,et al.  Transarterial embolectomy in acute stroke. , 2003, AJNR. American journal of neuroradiology.

[10]  P. Marx,et al.  Intravenous tPA for Ischemic Stroke: Team Performance Over Time, Safety, and Efficacy in a Single-Center, 2-Year Experience , 2001, Stroke.

[11]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .

[12]  W. Rosamond,et al.  Prehospital and Emergency Department Delays After Acute Stroke: The Genentech Stroke Presentation Survey , 2000, Stroke.

[13]  A. Furlan,et al.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.

[14]  Joakim Bjorkdahl.  Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience.: , 2000 .

[15]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[16]  R. O’Connor,et al.  Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. , 1999, Annals of emergency medicine.

[17]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[18]  R. Luepker,et al.  Delayed Hospital Arrival for Acute Stroke: The Minnesota Stroke Survey , 1998, Annals of Internal Medicine.

[19]  J. Grotta,et al.  Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.

[20]  C. Warlow,et al.  Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke , 1997, The Lancet.

[21]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[22]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[23]  A. Arboix,et al.  [Latency in the hospital admittance of stroke]. , 1995, Revista de neurologia.